European Green Transition (AIM: EGT), a company seeking to acquire and transform revenue stage businesses supporting the green energy transition in Europe, announces the appointment of Mick Kearney as an
Poolbeg Pharma (AIM: POLB) Interim Results for the six months to 30 June 2025
Well-funded with multiple upcoming clinical milestones
European Green Transition: From Exploration to Execution at The Investor Summit
A Company in Transition
Poolbeg Pharma (AIM: POLB) POLB 001 Phase 2a Trial Update
ACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost Trial to take place at The Christie NHS Foundation Trust and other leading UK
European Green Transition (AIM: EGT) Interim results and M&A strategy update
European Green Transition (AIM: EGT), a company which aims to capitalise on the opportunities created by the green energy transition in Europe, announces its unaudited results for the six months
hVIVO plc – Unaudited Interim Results for Six Months Ended 30 June 2025
Interim results Trading in line with expectations for full year Returning to growth in 2026
European Green Transition: From Exploration to Execution at The Investor Summit
A Company in Transition
hVIVO plc (AIM: HVO) Appointment of Non-Executive Chair
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that, further to its announcement on 29 July 2025, Shaun
hVIVO plc (AIM: HVO) Proposed appointment of Chair
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation and the world leader in human challenge clinical trials, announces the appointment of Shaun Chilton as Non-Executive Chair, subject to successful completion of
hVIVO PLC (AIM:HVO) Notice of Trading Update
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that it will issue a trading update for the six months ended 30
Poolbeg Pharma: New Capital, New Catalysts as POLB 001 Advances in the Clinic
Poolbeg Pharma plc (AIM: POLB) has entered 2025 with renewed momentum and a clear strategic focus following an oversubscribed £4.865 million equity raise and a series of high-impact developments across
hVIVO PLC (AIM:HVO) Positive results from client Phase 2b field study
Positive topline results from client Phase 2b field study